196 completed, 13 terminated, 12 unknown, 10 recruiting. 246 Phase 1, 34 Phase 2.
Follow Hyperlipidemias: new trials by email Literature Review of Hyperlipidemias trials Research Report on Hyperlipidemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C) Drug: EDIT-401, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 1 / Phase 2 | Not yet recruiting | Editas Medicine, Inc. | 56 | 2026-11-01 | 2026-10-26 |
| A Phase 1 Study of VELA-101 in Adult Participants VELA-101, Placebo - Healthy Participants, Hyperlipidemia | Phase 1 | Not yet recruiting | Ursa Medicines | 60 | 2026-11-01 | 2026-10-15 |
| A Study to Evaluate COR-2003 as Monotherapy and Co-Administered With COR-1004 in Adult Volunteers COR-2003, Placebo, COR-1004 + COR-2003 - Otherwise Healthy Individuals With Systolic Blood Pressure (SBP) From 110 to 139 mmHg and Low-density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL | Phase 1 | Not yet recruiting | Corsera Health | 108 | 2026-10-01 | 2026-10-05 |
| A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B Treatment A(AD-236A), Treatment B(AD-236B), Treatment C(AD-236A+AD-236B) - Hyperlipidemia, Diabete Type 2 | Phase 1 | Not yet recruiting | Addpharma Inc. | 44 | 2026-07-29 | 2026-07-28 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0167 in Healthy Participants SAL0167 group, SAL0167 placebo group - Hyperlipidemia | Phase 1 | Not yet recruiting | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 120 | 2026-07-21 | 2026-07-23 |
| A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C) STX-1150 - Elevated LDL-C and High Cholesterol | Phase 1 | Recruiting | Monash University | 64 | 2026-06-30 | 2026-09-21 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults Test Drug, Reference Drug - Hypercholesterolemia, Dyslipidemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 41 | 2026-06-11 | 2026-07-10 |
| A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults Laroprovstat/ezetimibe FCDP, Laroprovstat STP, Ezetimibe STP - Healthy Participants | Phase 1 | Completed | AstraZeneca | 18 | 2026-06-10 | 2026-09-28 |
| A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participants HRS-1301 Tablets, Atorvastatin Calcium Tablets, Midazolam oral solution - Hyperlipidemias | Phase 1 | Completed | Shandong Suncadia Medicine Co., Ltd. | 16 | 2026-06-08 | 2026-09-30 |
| A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults AZD4954, Laroprovstat - Healthy Participants | Phase 1 | Completed | AstraZeneca | 31 | 2026-04-10 | 2026-08-04 |
| A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2 - Healthy Participants | Phase 1 | Completed | AstraZeneca | 44 | 2026-03-16 | 2026-06-17 |
| Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy Volunteers RN5681, Placebo control - High Cholesterol | Phase 1 | Recruiting | Ikaria Bioscience Pty Ltd | 60 | 2026-03-12 | 2026-04-03 |
| First-in-Human Study of ISH0688: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics ISH0688 for injection, Placebo - Healthy Subjects, Hyperlipidemia, Hypertriglyceridemia | Phase 1 | Not yet recruiting | SUNHO（China）BioPharmaceutical CO., Ltd. | 104 | 2026-03-01 | 2026-04-01 |
| A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C Treatment A(AD-231A), Treatment B(AD-231B+AD-231C), Treatment C(AD-231A+AD-231B+AD-231C) - Hypertension, Hyperlipidemia | Phase 1 | Not yet recruiting | Addpharma Inc. | 55 | 2026-01-23 | 2025-12-31 |
| A Study of HRS-1301 Tablets in Healthy Subjects and Those With Impaired Kidney Function HRS-1301 Tablet - Hyperlipidemias | Phase 1 | Completed | Shandong Suncadia Medicine Co., Ltd. | 36 | 2026-01-13 | 2026-09-30 |
| Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia ARO-DIMERPA, Placebo - Hyperlipidemia; Mixed | Phase 1 / Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 78 | 2025-12-22 | 2026-10-13 |
| A Study to Evaluate COR-1004 in Adult Volunteers. COR-1004, Placebo - Hyperlipidemia | Phase 1 | Recruiting | Corsera Health | 80 | 2025-11-28 | 2026-10-26 |
| A Clinical Trial of HRS-1301 on the Pharmacokinetics of Rosuvastatin Calcium Tablets in Healthy Subjects HRS-1301 Tablets, Rosuvastatin Calcium Tablets - Hyperlipidemia | Phase 1 | Completed | Shandong Suncadia Medicine Co., Ltd. | 16 | 2025-10-09 | 2026-01-09 |
| a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia JMT202 injection, Placebo - Hypertriglyceridemia | Phase 1 / Phase 2 | Recruiting | Shanghai JMT-Bio Inc. | 48 | 2025-09-09 | 2025-12-30 |
| Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets Bempedoic acid film coated tablet, Nilemdo® Film-coated tablets - Hypercholesterolaemia | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 32 | 2025-05-21 | 2025-09-12 |
Showing 20 of 246. Sign in to see all of them.
Hypercholesterolemia (105) · Hypertriglyceridemia (38) · Hypertension (34) · Dyslipidemias (27) · Hyperlipoproteinemia Type II (19) · Cardiovascular Diseases (12) · Obesity (10) · Atherosclerosis (9) · Diabetes Mellitus (9) · Lipid Metabolism Disorders (8) · Metabolic Diseases (8) · Coronary Artery Disease (5) · Metabolic Syndrome (5) · Diabetes Mellitus, Type 2 (4)
Nutritional and Metabolic Diseases (245) · Lipid Metabolism Disorders (238) · Metabolic Diseases (238) · Dyslipidemias (219) · Vascular Diseases (47) · Cardiovascular Diseases (43) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (25) · Genetic Diseases, Inborn (24) · Lipid Metabolism, Inborn Errors (24) · Hyperlipoproteinemias (22) · Metabolism, Inborn Errors (22) · Glucose Metabolism Disorders (20) · Pathological Conditions, Signs and Symptoms (18) · Arterial Occlusive Diseases (14)
Rosuvastatin Calcium (19) · Atorvastatin (18) · Ezetimibe (10) · alirocumab (10) · Telmisartan (6) · bococizumab (6) · Amlodipine (5) · Metformin (5) · Simvastatin (5) · Drug Evaluation (4) · Niacin (4) · Omacor (4) · fimasartan (4) · gemcabene (4) · pitavastatin (4)
Pfizer (15) · AstraZeneca (11) · Sanofi (9) · Merck Sharp & Dohme LLC (8) · Addpharma Inc. (6) · Chong Kun Dang Pharmaceutical (6) · Novartis Pharmaceuticals (6) · Boryung Pharmaceutical Co., Ltd (5) · Jeil Pharmaceutical Co., Ltd. (5) · Jiangsu HengRui Medicine Co., Ltd. (4) · Organon and Co (4) · Shandong Suncadia Medicine Co., Ltd. (4) · Yuhan Corporation (4) · Arrowhead Pharmaceuticals (3) · Eli Lilly and Company (3)
United States (85) · South Korea (40) · China (33) · Canada (18) · Australia (17) · United Kingdom (16) · New Zealand (9) · Germany (6) · Netherlands (6) · Belgium (5) · France (3) · India (3) · Brazil (2) · Israel (2) · Japan (2)
Kyun Seop Bae, MD (2) · Michael H Davidson, MD, FACC (2) · Werner Siegmund, Prof (2) · Adrian Di Bisceglie, MD,FACP,FAASLD (1) · Alan K Copa, PharmD (1)
PMID 37994400, PMID 28181260, PMID 40587053, PMID 31776293, PMID 15324521, PMID 18068514, PMID 19500003, PMID 19833861, PMID 19843338, PMID 20457158, PMID 21120461, PMID 21252253, PMID 21417623, PMID 21593349, PMID 21831304, PMID 22435370, PMID 22743313, PMID 23638799, PMID 23706094, PMID 24077434, PMID 24094767, PMID 24206527, PMID 25202920, PMID 25256660, PMID 25393536, PMID 25889044, PMID 25942458, PMID 26261033, PMID 26607938, PMID 27184170, PMID 27287699, PMID 27959715, PMID 27986651, PMID 28391875, PMID 28538111, PMID 28538136, PMID 28636184, PMID 29037448, PMID 29844318, PMID 30243503, PMID 30623096, PMID 31242752, PMID 31329855, PMID 31630414, PMID 32080823, PMID 32473640, PMID 33183320, PMID 33647189, PMID 33900278, PMID 33969434
2015 (5), 2009 (1), 2019 (1), 2025 (1), M01RR000334 (1), P01HL059407 (1), R21AG023805 (1), R21NR011281 (1), U01AI068632 (1), U54DK083912 (1)